Introduction
Follow-up instead of immediate fine-needle aspiration (FNA) has been recommended for most adults with thyroid nodules ≤ 1 without extrathyroidal extension or apparent lymph node involvement on ultrasonography (US) [1] [2] [3] . In this situation, active surveillance has been considered when FNA is obtained and is suspicious or diagnostic of non-aggressive papillary thyroid carcinoma (PTC) [1, 3] . Indeed, studies have shown a low frequency of progression of lowrisk papillary thyroid microcarcinomas (PTMC) in adults [3] [4] [5] [6] [7] [8] . However, most of these studies involved Japanese and Korean populations, which accounted for more than 80 % of the patients studied [3] . To our knowledge, among studies conducted in other countries, only one North American study [5] and a Columbian study [8] have been published. Population differences in terms of the acceptance of active surveillance instead of immediate intervention and the natural history of low-risk PTMC are possible. In fact, although the American Thyroid Association has endorsed follow-up without FNA of nodules ≤ 1 cm and the possibility of no immediate intervention in the case of low-risk PTMC, it emphasizes the need to evaluate this management in populations other than the Japanese population [1] .
We therefore report here the results of a prospective study that evaluated the acceptance of active surveillance in adult patients diagnosed with low-risk PTMC and the frequency of short-term progression of these non-operated tumors.
Active Surveillance in Adults with Low-Risk Papillary Thyroid Microcarcinomas: A Prospective Study

AbstR AC t
The acceptance and results of active surveillance in patients with low-risk papillary thyroid microcarcinomas (PTMC) are unknown in populations other than the Japanese population. This was the objective of the present prospective study. We selected patients ≥ 20 years who had thyroid nodules ≤ 1.2 cm with intermediate or high suspicion for malignancy on ultrasonography (US), not located near the recurrent laryngeal nerve and without extrathyroidal invasion or apparent lymph node metastases, whose cytology was suspicious (Bethesda V) or diagnostic (Bethesda VI) of papillary thyroid carcinoma. Patients who opted for active surveillance were followed up by biannual US. Fifteen patients (18.7 %) readily opted for surgery and 12 (15 %) for active surveillance. Fifty-three patients (66.2 %) delegated the decision or wished to know the doctor's preference before deciding. After the doctor had declared his/ her preference for active surveillance, 50 patients decided to have this management and three to have surgery. Only 1/70 patients exhibited tumor progression (growth associated with a suspicion of extrathyroidal invasion) after 30 months of follow-up. Two patients decided to have surgery during follow-up, although the indication was not defined by the study. A > 50 % reduction in tumor volume was observed in three patients. The study shows that active surveillance can be well accepted if doctors were convinced that it is the best option for patients with low-risk PTMC. At least the short-term results reproduced those observed in other populations, with tumor progression being uncommon.
Patients and Methods
This was a prospective study started in January 2016 whose results were obtained up to 30 June 2019. The study was approved by the local Research Ethics Committee. The selection criteria and protocol were pre-defined and rigorously followed.
Patients
Adults (age ≥ 20 years) with thyroid nodules ≤ 1.2 cm consecutively seen during the period reported above, who met the inclusion criteria (▶ Fig. 1) , were initially selected. An additional evaluation was performed by the author (P.W.R.) to exclude patients classified as high risk and who were not candidates for active surveillance. Six patients were excluded during this step (▶Fig. 1).
Definition of management
For analysis of the acceptance of active surveillance, 15 patients who had been referred because they did not wish to undergo surgery (pre-defined option) were excluded. The remaining patients who had not made a decision at the time of inclusion in the study were offered the options of active surveillance or immediate surgery. Two pre-established conditions that needed to be followed were that the doctor would only express his/her preference (which is active surveillance) if requested by the patient and that he/she would not question or argue against the patient's decision for immediate surgery.
Follow-up and tumor progression
For analysis of tumor progression, patients with a previous preference for follow-up and those who opted for this management on the occasion of the study were included (▶Fig. 1). US was obtained every 6 months and the following parameters were evaluated: growth ≥ 3 mm, tumor volume increase ≥ 50 % (calculated using the ellipsoid equation: π/6 × length × width × height), suspicion of extrathyroidal invasion [9] , and suspicion of lymph node metastases [9] [10] [11] . In patients with TSH > 2.5 mIU/l in two consecutive measurements, levothyroxine (L-T4) was started to maintain TSH between 0.5-2 mIU/l. This target was the same in the few cases that already used L-T4 (n = 4) before the study.
In each patient, the initial US and those obtained during active surveillance were performed by the same examiner. Considering that the tumors had a maximum size of 1.2 cm, increases of ≥ 3 mm in diameter or ≥ 50 % in volume, as adopted in all previous studies [4] [5] [6] [7] [8] , would not be attributed to intraobserver variation [12] . 
Surgical indication during follow-up
The following conditions were considered surgical indications: (i) tumor growth associated with a size > 1.2 cm or suspicion of extrathyroidal invasion, or (ii) appearance of suspicious lymph nodes on US with confirmation of the metastatic nature by FNA. A growth ≥ 3 mm or tumor volume increase ≥ 50 %, but maintaining a size ≤ 1.2 cm in the absence of a suspicion of extrathyroidal invasion or lymph node metastases, was not considered a surgical indication and the patient remained under active surveillance. Obviously, if the patient expressed the desire for treatment at any time, regardless of the previous criteria, this wish was respected without the doctor arguing against it.
Results
The characteristics of the patients included in the study are shown in ▶ table 1.
Acceptance of active surveillance
In the case of patients who had not made a decision on the occasion of inclusion in the study (n = 80), 15 (18.7 %) readily opted for surgery and 12 (15 %) for active surveillance after the two options were given. Fifty-three patients (66.2 %) delegated the decision to the doctor or wished to know his/her preference before deciding. After the doctor had expressed his/her preference for active surveillance, 50 patients finally opted for this management and three for surgery. Comparing patients who opted for active surveillance versus immediate surgery, a personal history of non-thyroid malignancy and the presence of two tumor foci were significantly more frequent in the latter (▶ table 2) . In 8/77 (10.4 %) patients who opted for active surveillance, L-T4 was started to maintain TSH between 0.5-2 mIU/l.
Tumor progression
During closure of the results, seven patient had not yet undergone the second evaluation (6 months). In addition to the initial assessment, the number of biannual evaluations was 6 in 18 patients, ≥ 5 in 24, ≥ 4 in 36, ≥ 3 in 45, ≥ 2 in 55, and ≥ 1 in 70. Only one patient exhibited tumor progression after 30 months of follow-up, which led to the indication of surgery. In this case, US showed tumor growth associated with a suspicion of extrathyroidal invasion, but no lymph node metastases. Two patients decided to undergo surgery during follow-up, although they had no indication defined by the study. Since there was only one case, we did not analyze pre-▶table 1 Characteristics of the patients studied.
Patients evaluated regarding acceptance of active surveillance (n = 80)
Patients evaluated regarding tumor progression during active surveillance (n = 77)
Sex 
Additional information
Among adults ≥ 20 years with nodules ≤ 1.2 cm who were submitted to FNA but excluded from the study because cytology was not suspicious or diagnostic of PTC, 21 patients had highly suspicious nodules on US [1] and Bethesda cytology I (on two occasions), III (on two occasions), or IV. In these situations (combination of US and FNA), the risk of malignancy exceeds 50 % in our experience [13] [14] [15] [16] , and the patients were also followed up by US every 6 months. The number of biannual evaluations (after initial assessment) was 6 in 5 patients, ≥ 5 in 7, ≥ 4 in 10, ≥ 3 in 12, ≥ 2 in 15, and ≥ 1 in 21. None of the patients exhibited progression of the nodule or dropped out of active surveillance. Although presenting criteria for active surveillance, 20 patients opted for surgery (18 at the beginning of the study and 2 during follow-up). According to the 8th edition of the TNM classification [17] , none of the tumors was staged as T3b or T4 and all tumors were ≤ 1 cm on histology (T1a). Central lymph node involvement was suspected during perioperative evaluation and histology con-firmed metastases in 1 patient (5 %; cN1a). None of the patients had elevated serum thyroglobulin or a suspicion of metastases in the first assessment and 12 months after surgery. Distant metastases were therefore considered to be absent (M0).
Discussion
Active surveillance was well accepted (80 %) in the present study. FNA demonstrating malignancy was necessary for inclusion in the study. It is possible that more patients would opt for follow-up if they had only a diagnosis of a small thyroid nodule for which the doctor did not request a biopsy instead of receiving a diagnosis of malignancy after being submitted to FNA [18] . Thus, one strategy that could increase the acceptance of active surveillance is a follow-up in which FNA is not obtained for suspicious nodules ≤ 1 cm without extrathyroidal extension or apparent lymph node involvement on US and that do not affect a worrisome site. In fact, this is the current recommendation of ATA [1] , ETA [2] , and some experts [3] . It is also important to stress that, because this was a prospective study using a standardized approach, the doctor did not argue in favor of active surveillance when it was not requested or when ▶table 2 Comparison of patients who opted for active surveillance versus immediate surgery.
Immediate surgery (n = 18)
Active surveillance FNA: Fine-needle aspiration; PTC: Papillary thyroid carcinoma. a p = 0065, b p = 0.0032, c p = 0.0082, d p = 0.0042.
the patient decided to have surgery. In clinical practice in which the doctor could argue in favor of his/her preference (in this case, active surveillance), more patients might be convinced to opt for follow-up.
With respect to factors that may have contributed to the acceptance of active surveillance, although it is medical-scientific literature, the various guidelines on the subject are accessible on the internet and there has been absolute consensus in recent years that FNA is not necessary in the case of nodules ≤ 1 cm and that surgery is not readily required in low-risk PTMC. We believe that this conveys to the patient the idea that active surveillance is already a reality and a consistent option rather than an exceptional or still experimental management. There is also a growing body of literature showing that some patients may remain symptomatic or unsatisfied with L-T4 replacement as it is currently done. We believe that this causes greater resistance in patients to remove, even if partial, their functionally normal gland. We highlight these two aspects because, although not objectively and quantitatively evaluated, many patients reported to have searched the internet for information on these topics before making their decision. However, we recognize that the importance of these factors is probably influenced directly by the educational level of the patients and these factors had therefore greater relevance in this study.
Another factor that also seems to be important is convincing the doctor. Most of the patients (2/3) wanted to know the doctor's preference before making their decision and, after the doctor expressed his/her preference, almost all patients followed the same option or trusted the doctor with the best choice. According to the study protocol, in these cases, the doctor did not omit his/her opinion and clearly expressed the preference for active surveillance. Even if presenting the two options to the patients, we believe that the acceptance of active surveillance is much compromised if the physician does not transmit safety regarding this option, and especially if he/she expresses preference, even if hidden, for surgery. The experience of the Kuma Hospital in Japan shows that the frequency of active surveillance in PTMC increased from 30 % between 1993-1997 to 88 % between 2014-2016 [19] . Interestingly, in the last triennium, the frequency of active surveillance reached 97 % among endocrinologists who prefer it more often than surgeons [19] . This observation and the results of the present study suggest that acceptance by the patient does not seem to be a problem when it is addressed by a physician who is convinced that active surveillance is the best option.
Regarding tumor progression, we recognize the short study period. Nevertheless, the initial results are similar to those reported in series with a longer follow-up time involving other populations [4] [5] [6] [7] . A recent review of previous studies showed the absence of distant metastases in approximately 2500 patients with low-risk PTMC submitted to active surveillance, and only 1 % of the patients developed lymph node metastases apparent on US [3] . The frequency of tumor growth (increase ≥ 3 mm) was on average 5 % [3] , even in studies with longer follow-up [4, 6] . Since we had only one case of tumor progression, it was not possible to analyze predictive factors. As the most commonly found predictor, patient age has been related to the risk of tumor growth, which is higher in young individuals [4] [5] [6] [7] . Interestingly, as observed in three of our patients, tumor reduction has also been reported in other series at a frequency ranging from 5-15 % [5, 6, 20, 21] .
A reassuring fact in active surveillance is that disease-free survival in patients subsequently undergoing surgery does not seem to be compromised by postponement of the procedure. Taken together the data of 4 series [4] [5] [6] [7] , the review cited above showed that among 303 patients who underwent surgery after a period of active surveillance, highlighting that most of them did not receive radioactive iodine, only one case of short-term local recurrence (0.35 %) was observed [3] .
Finally, we included tumors measuring up to 1.2 cm for active surveillance. Other series also included tumors of up to 1.5 cm [5, 8, 22] and no difference in outcomes has been found so far for microcarcinomas and PTC between 1 and 1.5 cm [5, 22] . In agreement, in the case of hypoechoic nodules (intermediate suspicion), FNA was traditionally recommended for nodules > 1 cm, while the new recommendations of the American College of Radiology now indicate FNA for nodules > 1.5 cm [23] . It should also be noted that only 6/95 patients (6.3 %) would be considered "ideal candidates" [24] for active surveillance (data not shown). In the study of Tuttle et al. [5] , only 5 % of the patients were "ideal candidates". This fact shows that, in practice, the adoption of this restricted criterion may impede active surveillance.
The results suggest that active surveillance can be very well accepted if doctors are convinced that it is the best option for patients with low-risk PTMC. Regarding the progression of these tumors, at least in the short term, the results were similar to those observed in other populations, with tumor progression being uncommon.
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